Cervomed announces new data from phase 2b trial demonstrating neflamapimod's potential as a treatment for dementia with lewy bodies

Significant improvement relative to placebo on primary outcome measure, change in clinical dementia rating sum of boxes (cdr-sb), demonstrated in a within-subject analysis in participants with low likelihood of having alzheimer's disease (ad) co-pathology
CRVO Ratings Summary
CRVO Quant Ranking